07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

XEN-D0103: Phase II started

Xention began the double-blind, placebo-controlled, crossover, U.K. Phase II XAPAF trial to evaluate 50 mg oral XEN-D0103 twice daily for 28 days in 20 patients with paroxysmal AF who have implanted pacemakers. Last year, Xention...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Company News

Xention, Servier deal

Xention granted Servier an option to acquire rights to develop and commercialize XEN-D0103 for atrial fibrillation (AF), excluding the U.S. and Japan. During the undisclosed option period, the companies will jointly conduct two Phase II...
00:22 , Oct 3, 2013 |  BC Extra  |  Company News

Xention grants Servier option to AF compound, XEN-D0103

Xention Ltd. (Cambridge, U.K.) granted Servier (Neuilly-sur-Seine, France) an option to acquire rights to develop and commercialize atrial fibrillation (AF) compound XEN-D0103 , excluding the U.S. and Japan. During the undisclosed option period, the companies...
07:00 , Mar 18, 2013 |  BioCentury  |  Emerging Company Profile

Acesion: Accessing SK in AF

Acesion Pharma ApS is going after a new target in atrial fibrillation - SK channels. The NeuroSearch A/S spinout expects its small molecule inhibitors to have fewer side effects than marketed AF drugs. Marketed drugs...
07:00 , Mar 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Fibrillation; arrhythmia Potassium channel Kv1.5 (KCNA5) In vitro and in vivo studies suggest a new class of KCNA5 inhibitors could...
01:10 , Nov 24, 2010 |  BC Extra  |  Financial News

Xention raises L8 million

Xention Ltd. (Cambridge, U.K.) raised L8 million ($12.8 million) in a series D round led by new investor Seroba-Kernel Life Sciences. Existing investors Forbion Capital Partners; Credit Agricole; MVM; and BTG International participated. Seroba-Kernel's Graham...